Home About us Editorial board Ahead of print Current issue Archives Instructions Submit article Search Subscribe Contacts Login
  • Users Online: 307
  • Home
  • Print this page
  • Email this page
Year : 2022  |  Volume : 9  |  Issue : 2  |  Page : 70-81

Newer indications of tranexamic acid in dermatology beyond melasma: a review

Department of Dermatology and Venereology, Government Medical College and Hospital, Chandigarh, India

Correspondence Address:
Dr. Mala Bhalla
Department of Dermatology and Venereology, Government Medical College and Hospital, Chandigarh 160030
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/pigmentinternational.pigmentinternational_

Rights and Permissions

Tranexamic acid (TXA) is an antifibrinolytic agent approved for use to control bleeding during surgery and after trauma. It has been used in dermatology as a therapeutic and prophylactic agent in angioedema since 1970s but its recently discovered role in melasma has made it the current molecule of interest. At present TXA is being widely researched for multiple indications in view of its role in reducing melanogenesis and angiogenesis in skin. Various case reports and clinical trials have been published over the last few years describing its role in postinflammatory hyperpigmentation, dermal melanosis, rosacea, telangiectasia, and even as an antiaging agent. We present this review here summarizing the various publications for the aforementioned indications.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded204    
    Comments [Add]    

Recommend this journal